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Abstract
Obesity is one of the largest health problems facing the world today. Although twin and family studies suggest about two-
thirds of obesity is caused by genetic factors, only a small fraction of this variance has been unraveled. There are still large
numbers of genes to be identified that cause variations in body fatness and the associated diseases encompassed in the
metabolic syndrome (MetS). A locus near a sequence tagged site (STS) marker D6S1009 has been linked to obesity or body
mass index (BMI). However, its genetic entity is unknown. D6S1009 is located in the intergenic region between SLC35D3 and
NHEG1. Here we report that the ros mutant mice harboring a recessive mutation in the Slc35d3 gene show obesity and MetS
and reduced membrane dopamine receptor D1 (D1R) with impaired dopamine signaling in striatal neurons. SLC35D3 is
localized to both endoplasmic reticulum (ER) and early endosomes and interacts with D1R. In ros striatal D1 neurons, lack of
SLC35D3 causes the accumulation of D1R on the ER to impair its ER exit. The MetS phenotype is reversible by the
administration of D1R agonist to the ros mutant. In addition, we identified two mutations in the SLC35D3 gene in patients
with MetS, which alter the subcellular localization of SLC35D3. Our results suggest that the SLC35D3 gene, close to the
D6S1009 locus, is a candidate gene for MetS, which is involved in metabolic control in the central nervous system by
regulating dopamine signaling.
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Introduction
The worldwide prevalence of obesity (OMIM 601665, http://
www.ncbi.nlm.nih.gov/omim/) is increasing (data from the
International Obesity Taskforce (IOTF) website, http://www.
iaso.org/iotf/obesity/). This has resulted in a significant increase
in morbidity and mortality associated with the metabolic
syndrome (MetS, OMIM 605552). Obesity and associated MetS
or body mass index (BMI, OMIM 606641) are regarded as
complex traits influenced by both additive genetic effects and
environmental factors [1]. It has been estimated that genetic
factors explain 67% of the variance in human obesity [2].
Currently, more than 150 loci have been implicated in the
development of monogenic obesity, syndromic obesity and
polygenic obesity. However, only about 2% of the variance in
this trait has been explained [3,4]. About 200 cases of severe
obesity have been reported to be associated with a single gene
mutations in a cohort of 11 genes [5]. Studies on extremely obese
children have been successful in the characterization of the
causative genes for monogenic obesity. However, progress with
this approach has been very slow, and is expected to be faster in
the era of whole exome sequencing. On the other hand, the
identification of the FTO gene as an obesity gene is an example of
loci uncovered by genome-wide association or linkage studies [6].
It remains a challenge to uncover genes responsible for mild or
moderate obese phenotypes, especially those which develop in
adulthood.
Genome-wide linkage analyses have revealed that a locus on
chromosome 6q23-25 is linked to obesity in the Framingham
Heart Study, with a major locus near the sequence tagged site
(STS) marker D6S1009 [7–9]. D6S1009 is located within the
intergenic region between SLC35D3 (55,419 bp apart at the
centromere side) and NHEG1 (867 bp apart at the telomere side)
in the NCBI Map Viewer (http://www.ncbi.nlm.nih.gov/
mapview/). NHEG1 (neuroblastoma highly expressed 1) is a
predicted gene with unknown function. No association with
obesity of this gene has been documented. SLC35D3 (solute
carrier family 35, member D3) is predicted as an orphan
nucleotide sugar transporter or a fringe connection-like
protein with 10 transmembrane domains. Previous studies have
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characterized the recessively inherited ros-/2 mutant mouse (ros
hereafter), which has a spontaneous intracisternal A particle (IAP)
insertion at the first exon of the Slc35d3 gene to disrupt its function
[10]. Platelet dense granules are absent in the ros mutant,
suggesting that SLC35D3 is involved in the biogenesis of platelet
dense granules [10,11]. This function seems not to do with the
solute carrier, and requires further investigation. Mouse Slc35d3 is
specifically expressed in the brain as determined by multiple tissue
Northern blots [10], suggesting it has specific roles in the central
nervous system. In addition, Slc35d3 expression was restricted to
the striatonigral medium spiny neurons (MSNs) expressing
dopamine receptor D1 (D1R) rather than the striatopallidal
MSNs expressing dopamine receptor D2 (D2R) [12]. Interestingly,
during the breeding of this mouse, we observed that the adult ros
mice gained weight progressively. Here we have characterized the
ros mutant as a mouse model of MetS and obesity. In addition, we
found two MetS patients with mutations of the SLC35D3 gene.
Our results suggest that SLC35D3 is a candidate gene for obesity-
related MetS, which is involved in metabolic control in the central
nervous system by regulating dopamine signaling.
Results
Ros mutant exhibits metabolic syndrome and lowered
energy expenditure
During the breeding of the ros mutant mice, we observed that
adult ros mice became obese compared to sex and age-matched
wild-type (WT) mice (Fig. 1A). Growth curves showed progressive
and significant weight gain of ros mice relative to WT controls,
starting at 8 weeks in males, which is similar to the features of late-
onset obesity in humans. However, the expression levels of
SLC35D3 in the striatum did not change at different postnatal
stages within 6 months (Fig. S1). Based on this observation, we
chose mice at 12 weeks of age for behavior and molecular tests,
mice at 24 weeks of age for phenotypic analyses of MetS. At 24
weeks of age, ros males were 31.5% heavier than age-matched WT
males (Fig. 1B), while the naso-to-anal body length was increased
by 6.2% in ros mice relative to WT controls (Fig. 1C).
To determine whether the increased weight of ros mice reflects
body composition changes, we dissected and weighed two distinct
fat pads, epididymal and perirenal white adipose tissue (WAT).
Both epididymal and perirenal fat mass were enormously
increased in ros mice (Fig. 1D). Serum cholesterol and triglycerides
levels were increased about 19% and 61% respectively compared
with the WT controls (Figs. 1E and 1F). Blood glucose levels in ros
mice were increased about 43% (Fig. 1G). In addition, serum
insulin was increased about 4.2-fold in ros mice (Fig. 1H), while the
insulin tolerance test (ITT) and glucose tolerance test (GTT)
showed ros mice were insulin resistant and glucose intolerant
(Figs. 1I and 1J). Taken together, the ros mice exhibited multiple
features of the MetS with late-onset obesity, hyperlipidemia,
hyperglycemia and hyperinsulinemia.
The development of obese ros mice may result from elevated
energy intake and/or decreased energy expenditure. To assess
whether ros mice were hyperphagic, daily food intake was
monitored in animals fed a standard chow diet ad libitum for 7
consecutive days at the age of 24 weeks when rosmice were already
obese. There was no significant difference in daily food intake
between WT and ros mice (Fig. 2A). This suggests that energy
intake is unaffected in ros mice. On the other hand, ros mice had
significantly decreased physical activity including decreased
movement distance, average velocity and movement duration
(Figs. 2B–D).
The decreased physical activity in ros mice prompted us to
measure daily energy expenditure over 5 day periods using an
Oxymax system (details in the Materials and Method and Fig. S2).
Total energy expenditure (resting plus activity metabolism) in the
ros mice at age 2–3 months, prior to development of obesity, was
significantly lower than in the WT mice using analysis of
covariance (ANCOVA) [13] (Fig. 2E). However, there was no
difference between the genotypes in their resting metabolic rates,
independent of how the resting metabolism was evaluated (Figs. 2F
and 2G). This indicated that the difference in energy expenditure
between the genotypes was contributed to only by the differences
in physical activity expenditure. When we included distance
traveled in the respirometry chambers as a covariate in the analysis
of total metabolic rate, this only marginally reduced the effect of
genotype (F1,12 = 11.48, P=0.05), suggesting the impact of the
mutation is on the total amount of activity as well as the energy
costs of locomotion.
Plasma membrane D1R is reduced in ros striatonigral
neurons which impairs dopamine signaling
The brain-specific expression pattern in the multiple Northern
blots [10] indicated a restricted expression and specific function of
SLC35D3 in the brain. We detected no mutant SLC35D3 protein
in striatum, substantia nigra and olfactory bulb of the ros mutant
with an antibody to mouse SLC35D3 (Fig. 3A), although
transcription was upregulated in mutant tissues [10]. SLC35D3
protein was readily detectable in these tissues of WTmice (Fig. 3A).
Although the expression of SLC35D3 in the Allen Brain Atlas
(http://www.brain-map.org/) shows a wider distribution, in either
WT or mutant mice, we did not detect the SLC35D3 protein in
other brain sub-regions and especially in the obesity-related brain
tissues such as thalamus and hypothalamus (Fig. 3A), as well as in
several organs involved in energy homeostasis such as adipose
tissue, pancreas, liver and skeletal muscle (Fig. 3B). In addition, no
apparent morphological changes or fat accumulation was observed
in these organs (Figs. 3C–3F). Considering the enlargement of
WAT fat pads (Fig. 1D), the adipocytes in adult ros mice exhibited
hyperplasia (increase in number), rather than hypertrophy
(increase in size), to contribute mainly to the weight gain. The
presence of SLC35D3 in non-neuronal tissues is only known so far
in platelets and it plays a role in the biogenesis of platelet dense
granules [10,11]. These results suggest that SLC35D3 is selectively
expressed in certain types of neurons with particular enrichment in
the basal ganglia, and that ros mice allow us to investigate the
phenotypes related to its dysfunction in these neurons.
It has been reported that Slc35d3 is specifically expressed in the
striatonigral MSNs expressing D1R rather than the striatopallidal
Author Summary
Genome-wide linkage analyses have revealed that an STS
marker D6S1009 (about 55 kb from the SLC35D3 gene) is
linked to obesity or BMI in the Framingham Heart Study,
but its genetic entity is unknown. Here we characterized
the features of obesity and metabolic syndrome with
reduced physical activity levels in a previously identified
ros mouse mutant, carrying a homozygous Slc35d3
mutation. These ros phenotypes were caused by the
intracellular accumulation of D1R mostly on ER in the
striatal neurons, impairing D1R signaling and reducing
energy expenditure. In addition, we identified two
mutations of SLC35D3 in patients with metabolic syn-
drome which are subcellularly mislocalized. We propose
that the SLC35D3 gene is likely a novel candidate gene for
MetS and obesity.
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MSNs expressing D2R [12], therefore, we investigated whether
SLC35D3 regulates the function of D1 neurons. Immunohisto-
chemical analysis using an antibody to D1R showed that
numerous intensely immunoreactive cell bodies were present in
ros striatum (Fig. 4A), which is similar to the intracellular
accumulation or internalization of D1R after D1R agonist
treatment [14]. To confirm this, in immuno-electronic microscop-
ic (IEM) pictures labeled by anti-D1R, we quantified the gold-
labeled particles located on the plasma membrane (PM) and
endomembrane structures (EnM) (Fig. 4B). The proportion of
D1R in EnM was significantly higher (66%) in ros striatum than
that (48.3%) in wild-type (Fig. 4C).
We then tested cyclic AMP (cAMP) production to detect
functional D1R activation at the cell surface. Stimulation of D1R
by the specific agonist SKF82958 (10 mM) produced an
accumulation of cAMP in both groups. Consistently, cAMP
production in ros striatum was reduced about 36% compared with
theWT controls (Fig. 4D), which may be attributable to the reduction
of plasma membrane D1R. Western blotting of striatum lysates
showed that total D1 receptor expression levels were similar between
wild-type and ros samples (Fig. 4E), indicating the total number of
striatal D1 neurons in ros mice is not changed. In comparison, total
D2R and the fraction of D2R on the plasma membrane were
unchanged in the striatum of rosmutant mice (Fig. S3), consistent with
the observation that SLC35D3 is not expressed in the D2 neurons
[12]. This indicates that SLC35D3 plays a role in D1R trafficking in
the striatal D1 neurons, but does not affect D2R trafficking in the
striatal D2 neurons. Taken together, our results suggest that loss of
SLC35D3 in ros striatum causes intracellular accumulation of D1R
and reduces D1 receptors on the plasma membrane.
Figure 1. Ros mice exhibit features of metabolic syndrome. (A) Comparison of ros mouse and wild-type (WT) C3H/HeSnJ mouse at 24 weeks
of age. (B) Growth curves of male WT and ros mice. Body weights of ros mice are significantly higher than those of WT starting at 8 weeks. (C) ros
mice show significantly increased naso-to-anal body length (10.0660.09 cm, n= 10) compared with the WT controls (9.4760.06 cm, n = 10) at 24
weeks of age. (D) Perirenal and epididymal fat pad weight in ros mice (n = 10) are significantly higher than those of the WT (n = 10) respectively at 24
weeks of age. (E–G) Serum levels of cholesterol (Chol), triglycerides (TG) and blood glucose (Gluc) in fasted ros mice (n = 14) are significantly higher
than those in WT controls (n = 14) at 24 weeks of age. In ros, mean values of Chol, TG, Gluc are 3.82, 1.0, 11.47 mmol/L, respectively; In WT, mean
values of Chol, TG, Gluc are 3.21, 0.62, 8.03 mmol/L, respectively. (H) Plasma insulin levels were increased in non-fasted ros mice (3.6260.20 ng/ml,
n = 3) than in WT (0.8760.08 ng/ml, n = 3) at 24 weeks of age. (I) Insulin tolerance tests (ITT) showed a tendency of impaired tolerance in ros mice
compared with WT mice at 24 weeks of age (n = 3). (J) Glucose tolerance tests (ITT) showed a tendency of impaired tolerance in ros mice compared
with WT mice at 24 weeks of age (n = 3). *P,0.05, **P,0.01, ***P,0.001.
doi:10.1371/journal.pgen.1004124.g001
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SLC35D3 is localized to the ER and early endosomes and
it interacts with D1R
To ascertain the underlying mechanism of the accumulation of
D1R within the ros neurons, we first examined the subcellular
localization of mouse SLC35D3. Consistent with a recent report
[11], the EGFP-SLC35D3 protein was selectively localized to the
ER and early endosomes, but not to the Golgi apparatus or late
endosomes/lysosomes (Figs. 5A–5D).
We then investigated the intracellular location of accumulated D1R
in ros striatal neurons. We performed immuno-EM by double-labeling
with anti-D1R and anti-SEC61B (an ER marker) and found that the
D1R particles co-residing with SEC61B in ros striatal neurons (19.6%)
were significantly higher than that in wild-type (6.8%) (Fig. 5E). This
indicates that the increased proportion of ER-retained D1R (12.8%,
Fig. 5E) may mostly account for the reduction of plasma membrane
D1R (17.7%, Fig. 4B) in rosmice. OurOptiPrep gradient assays further
confirmed the shift of D1R from plasma membrane (fractions 16–25)
to intracellular fractions 2–10 mainly corresponding to ER in ros
striatum compared with the wild-type (Fig. 5F).
We then tested whether there is a physical interaction between
SLC35D3 and D1R by co-immunoprecipitation. Indeed, we
observed that Myc-SLC35D3 co-precipitated with Flag-D1R
(Fig. 6A). Reciprocally, Myc-D1R co-precipitated with Flag-
SLC35D3 (Fig. 6B). In addition, we found that the N-terminal
portion of SLC35D3 (1–241aa) interacted with the C-terminal
region of D1R (217- 446aa) (Figs. 6A, 6B).
Taken together, our results indicate that SLC35D3 is likely
involved in the membrane trafficking of D1R on its ER exit, and
that loss of SLC35D3 leads to the intracellular D1R retention
mainly on ER, thus reducing the amount of plasma membrane
D1R receptors and their signaling.
Mutational screen of human SLC35D3 in patients with
metabolic syndrome
The above findings in ros mice prompted us to investigate
whether there are mutations in the orthologous human SLC35D3
gene in patients with MetS. We screened 363 Chinese Han patients
withMetS and 217 unaffected individuals by sequencing the two exons
Figure 2. Food intake, spontaneous locomotor activity and total and resting energy expenditure. Mice at 12 weeks of age were used in
this study. (A) There was no significant difference in daily food intake between wild-type (WT) (n = 14) and rosmice (n = 15). P= 0.066. (B) The distance
traveled during 30 min for ros mice (n = 25) was lower than that for the WT (n = 20). (C) The average movement velocity during 30 min for ros mice
(n = 25) was shorter than the WT (n = 20). (D) The total movement duration during 30 min for rosmice (n = 25) was shorter than the WT (n = 20). (E–G)
Total energy expenditure (Watts) (E), resting energy expenditure (Watts) by Method 1 (F) and resting energy expenditure (Watts) by Method 2 (G) for
WT and ros mice measured at age 8 to 12 weeks (n = 8 per group). WT mice are black symbols and ros mice are white symbols. Fitted linear
regressions for each data set are shown. There was a significant effect of body weight and genotype but no interaction in total energy expenditure
(ANCOVA: Body weight effect, F1,13 = 44.85, p,0.001); genotype effect, F1,13 = 10.47, p = 0.007; interaction, not significant (ns).). There was a significant
effect of body weight but no genotype or interaction effect in resting energy expenditure by Method 1 or 2 (Method 1 ANCOVA: Body weight effect,
F1,13 = 8.78, p = .011; genotype effect, F1,13 = 0.35, p = 0.566; interaction: ns. Method 2 ANCOVA: Body weight effect, F1,13 = 22.29, p,0.001; genotype
effect, F1,13 = 0.03, p = 0.873; interaction, ns.). *P,0.05, **P,0.01.
doi:10.1371/journal.pgen.1004124.g002
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and adjacent exon/intron boundaries together with 1 kb untranslated
sequence upstream of the start codon of the SLC35D3 gene.
Two variants of SLC35D3 leading to the frame-shift of the
coding sequence were found in two unrelated patients. These
variants were absent in the control group or the NCBI SNP
database for the SLC35D3 gene (Locus ID 340146, http://www.
ncbi.nlm.nih.gov/SNP/). In patient #1 (Male, Age: 55, BMI:
26.1, waist circumference: 109 cm, blood pressure: 135/
85 mmHg, TG: 4.23 mmol/L, Chol: 5.28 mmol/L, Gluc:
4.4 mmol/L), a heterozygous DK404 was identified (Fig. 6C).
The mutated SLC35D3 showed the miscolocalization to LAMP3-
positive late endosomes/lysosomes in transfected cells compared
with WT protein (Fig. 6D), suggesting its subcellular localization
has been altered. In patient #2 (Male, Age: 51, BMI: 27.1, waist
circumference: 100 cm, blood pressure: 120/80 mmHg, TG:
2.52 mmol/L, Chol: 5.94 mmol/L, Gluc: 5.2 mmol/L), a heterozy-
gous insL201 was identified (Fig. 6C). Similarly, the mutant insL201
colocalized with LAMP3, but not EEA1 or SEC61B (Fig. 6D), also
Figure 3. SLC35D3 expression in brain sub-regions and non-neuronal tissues. Mice at 24 weeks of age were used in this study. (A)
Immunoblotting of SLC35D3 protein in nine brain sub-regions of wild-type (WT) and ros mice. OB: olfactory bulb, CC: cerebral cortex, HIP:
hippocampus, STR: striatum, THA: thalamus, HYP: hypothalamus, SN: substantia nigra, CB: cerebellum, BS: brain stem. (B) Immunoblotting assay
showed no expression of SLC35D3 in adipose tissue, pancreas, liver, or skeletal muscle compared with striatum or brain in WT mice. There was no
expression of SLC35D3 in any of these tissues in ros mice. b-actin serves as a loading control. (C) The size of adipose from epididymal fat pad of ros
mice was normal. (D–F) No apparent fat accumulation was observed in pancreas, liver, or skeletal muscle in rosmice. 2006magnification was applied
in the sections with H–E staining.
doi:10.1371/journal.pgen.1004124.g003
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suggesting that these mutations alter the subcellular localization of
SLC35D3. The residues around L201 are conserved in human,
chimpanzee, dog, mouse and rat. However, the residues around K404
are less conserved in these species. The mislocalization of these two
variants (insL201 and DK404) implicates localization or sorting signals
may lie on these mutational sites.
We did not find a second mutation in the SLC35D3 gene in
these two patients after excluding possible large deletions,
Figure 4. Plasma membrane D1R and its signaling are reduced in ros striatonigral neurons. Mice at 12 weeks of age were used in this
study. (A) Immunohistochemical detection of D1R on the coronal brain sections of the striatum. In ros mice, visible immunoreactive cell bodies are
present (arrows). Scale bar: 100 mm. (B, C) Representative immuno-EM pictures of D1R-labeled particles on plasma membrane (PM, upper panels) and
endomembrane structures (EnM, lower panels) in wild-type (WT) and ros striatal neurons are shown without much difference (B). However, the
quantification test revealed that the particles on PM in ros mice (34.0%, n = 103) is significantly lower than that in WT (51.7%, n = 87), **P,0.01. Scale
bar: 200 nm. (D) SKF82958–induced cAMP accumulation in striatal membranes prepared from WT and ros mice. As compared with the WT
(11.0960.61 pmol/ml, n = 6), cAMP activity in rosmembranes (7.1160.45 pmol/ml, n = 6) was reduced about 36%. *P,0.001. (E) Immunoblot analysis
of D1 receptor. left panel, Striatum tissues (20 mg) from WT and ros mice were probed with the monoclonal D1R antibody. b-actin was used as a
loading control. The immunoblots shown are representative of three independent experiments. right panel, Normalized percentages of the band
intensities shown in left panel are means 6 SEM (n= 3). There is no significant difference of total D1R levels between WT and ros mice (P.0.05).
doi:10.1371/journal.pgen.1004124.g004
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suggesting that both patients are likely affected in the heterozygous
state. Both patients were diagnosed as having MetS with central
obesity according to the guidelines of International Diabetes
Federation (IDF) [15] and central obesity in China [16]. Similarly,
we observed moderate weight gain in heterozygous ros+/2 mice at
5 months of age compared with WT littermates (WT: 29.460.38,
n = 7; ros+/2: 30.960.24, n= 8; P,0.01). The more severe weight
gain in homozygous ros2/2 mice at the same age is suggestive
that the SLC35D3 mutation may have a gene dosage effect on
D1R trafficking. It is unknown whether patients with homozygous
or compound mutations may have more severe phenotypes.
Unfortunately, we were not able to get access to the blood samples
of the family members of these two patients, which precluded us to
explore the penetrance of the mutations. This study suggests that
mutant human SLC35D3 does not function properly in the ER
exit of D1R, thus likely impairing the membrane trafficking of
Figure 5. Subcellular localization of SLC35D3 protein and the effect of SLC35D3 on trafficking of D1R. (A–D) In HEK293T cells, EGFP-
SLC35D3 co-localized with the ER marker SEC61B and the endosome marker EEA1, but not with the Golgi marker GM130 or the lysosome/late
endosome marker LAMP3. (E) Representative pictures to show that the smaller gold-labeled D1R particles (10 nm, arrowheads) and the larger gold-
labeled SEC61B particles (ER marker) (15 nm, arrows) are colocalized in ros striatum compared with the particles on different structures in wild-type
(WT) under immuno-EM at 12 weeks of age. Scale bar: 200 nm. The percentage of D1R colocalized with SEC61B in ros mutant (19.6%, n= 97) is
significantly higher than that in wild-type (WT) (6.8%, n = 74), *P,0.05. (F) Immunoblotting of Optiprep (Biocomp, USA) gradient (5–20%) fractions.
One microgram tissue lysates of striatum at 12 weeks of age were separated into 26 fractions. D1R was shifted from plasma membrane (PM: GluR1 as
a marker) in fractions 16–25 to intracellular fractions 2–10 mainly in endoplasmic reticulum (ER: BIP as a marker) in ros mice compared with WT mice.
IN: lysate input; M: molecular marker.
doi:10.1371/journal.pgen.1004124.g005
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D1R and D1 signaling in the patients in a similar mechanism as
revealed in ros mice.
D1R agonist reduces body weight and reverses
hyperlipidemia in ros mice
To test whether the pathological phenotype in obese ros mice is
reversible by the treatment with a D1R agonist, adult male mice
received a daily intraperitoneal injection of D1 receptor agonist
SKF38393. Following the 12-day treatment period, we observed
that body weight loss of ros mice (13%) was significantly higher
than that of the wild-type (7%). In contrast, body weight changes
of saline-treated wild-type mice or ros mice were not significant
(Fig. 7A). Treatment with SKF38393 did not change the levels of
serum lipids and glucose compared with saline-treatment in
Figure 6. SLC35D3 interacts with D1R and mutations of SLC35D3 alter its subcellular distribution. (A) C-terminal D1R interacted with
SLC35D3. Cell lysates with the co-expression of Myc-SLC35D3 and Flag-D1R (or Flag-D1R-NT (1–216aa), or Flag-D1R-CT (217–446aa)) were
immunoprecipitated. Both the full-length D1R and the D1R-CT bound with Myc-SLC35D3. (B) N-terminal SLC35D3 interacted with D1R. Cell lysates
with the co-expression of Myc-D1R and Flag-SLC35D3 (or Flag-SLC35D3-NT (1–301aa), or Flag-SLC35D3-CT (242–422aa)) were immunoprecipitated.
Both the full-length SLC35D3 and the SLC35D3-NT bound with Myc-D1R. (C) Two heterozygous mutations were identified in two patients with MetS.
WT: wild-type SLC35D3; MU: mutant SLC35D3. In patient#1, a 3-bp deletion (c.1209_1211delGAA) as underlined led to an in-frame deletion of K404.
In patient#2, a 3-bp insertion (c.601_602insCTG) as the arrow indicated led to an in-frame insertion of L201. (D) In HEK293T cells, wild-type SLC35D3
was partially colocalized with EEA1 (early endosome) and SEC61B (ER), without colocalization with LAMP3 (late endosome/lysosome). The DK404 and
insL201 mutations were mislocalized mainly on late endosomes/lysosomes.
doi:10.1371/journal.pgen.1004124.g006
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PLOS Genetics | www.plosgenetics.org 8 February 2014 | Volume 10 | Issue 2 | e1004124
wild-type mice. Strikingly, serum cholesterol and triglycerides
levels were significantly decreased for SKF38393-treated ros mice
to levels that were similar to those of wild-type mice. Blood glucose
levels in ros mice were significantly reduced after the treatment of
SKF38393 (Figs. 7B–7D). Thus, administration of SKF38393
caused body weight loss and rescued the hyperlipidemia in ros
mice. In addition, physical activity was increased significantly after
SKF38393 treatment in ros mice compared with WT (Fig. 7E).
These results suggest that impaired D1R signaling could be
reversible by D1R agonists in ros mice and likely in patients with
MetS who carry SLC35D3 mutations.
Discussion
Obesity is caused by perturbations of the balance between
energy intake and energy expenditure, which in turn is regulated
by a complex physiological system that requires the coordination
of several peripheral and central signals in the brain [17–19].
Dopaminergic signaling pathways are involved in the regulation of
food intake and energy expenditure, including the mesolimbic
pathway in food reward, the mesohypothalamic pathway in satiety
and the nigrostriatal pathway in energy expenditure [20–22]. Both
the D1 and D2 dopamine (DA) receptors act synergistically in the
regulation of the basal ganglia function in the striatal MSNs
[23,24]. Dysregulation of DA signaling has been previously
implicated in the development of obesity [25]. However, the
precise mechanism by which DA receptors regulate energy
balance is still unclear [26]. Positron emission tomography
revealed that striatal D2 receptor availability is lower in obese
humans compared to lean individuals [25,27], but to date no
human imaging studies have assessed the involvement of D1
receptors in obesity.
Reduction of DA receptors on the cell surface could result from
1) increased internalization, 2) reduced reinsertion to the plasma
membrane due to increased degradation, and 3) reduced
trafficking or expression ab initio. Previous extensive studies have
focused on understanding the internalization of DA receptors
following agonist occupancy, including agonist-elicited receptor
desensitization, endocytosis, and resensitization or degradation
[28–31]. Unlike D2R, which is generally trafficked to the
lysosomes for degradation [32], endocytosed D1R is recycled
back to the plasma membrane [14,33]. However, mechanistic
studies of the trafficking of D1R to the cell surface are limited [34],
and its relevance of this trafficking to metabolic disorders has not
been reported.
Transit out of the ER has been shown to be a critical control
point and rate-limiting step in the expression of D1 receptors at
the cell surface [35,36]. A number of DA receptor-interacting
proteins have been identified [37]. One ER protein, DRiP78, acts
as a chaperon for D1 receptor trafficking [35]. Similarly, our data
have shown that SLC35D3 is localized to the ER and endosomes,
where it interacts with D1R. Loss of SLC35D3 in ros mice blocks
the ER exit of D1R, thus leading to retention in the ER and
reduced D1R distribution on the cell surface, thereby impairing
D1R signaling. We have not completely excluded the possibility
that D1R trafficking from early endosomes to plasma membrane is
also blocked. Given that the ER-retained fraction of D1R accounts
for the greatest proportion of reduced plasma membrane D1R
(Figs. 4B and 5E), we speculate that SLC35D3 plays a major role
in the ER exit of D1R. Likewise, in human patients, the mutant
SLC35D3 (insL201 or D404K) is mistargeted to late endosomes/
lysosomes and therefore is likely unable to function properly in the
ER exit of D1R. Therefore, SLC35D3 is identified as a novel
regulator of D1R membrane trafficking from ER.
The restricted expression of SLC35D3 in the brain and the
absence of expression in other peripheral organs (except for the
platelets) laid the foundation of our hypothesis that the MetS
phenotype in ros mice is attributable to lesions in the central
nervous system. Since D2R distribution (Fig. S2) is unaffected, and
SLC35D3 was not expressed in D2 neurons [12], the impaired
D1R signaling perturbs the D1R/D2R balance, which likely led to
the reduced movement and energy expenditure due to the
dysfunction of the basal ganglion DA loop.
No apparent obesity phenotypes have been documented in
several D1r-knockout (KO) mouse lines as listed in the
MGI database (MGI:99578, http://www.informatics.jax.org/).
Figure 7. Effect of SKF38393 treatment on body weight loss,
serum lipids and glucose, and activity of wild-type or ros mice.
Mice at 24 weeks of age were used in this study. (A) Wild-type (WT) or
ros mice (n = 9 per group) received a daily intraperitoneal injection of
20 mg/kg SKF38393 for 12 days and weighed on day 14. Body weights
of saline-treated WT or ros mice had no significant changes, whereas
body weights of SKF38393-treated WT mice were reduced approx-
imately 7% (from 29.6160.76 g to 27.560.6 g), and body weights of
SKF38393-treated ros mice were reduced approximately 13% (from
38.5660.79 g to 33.3960.58 g). ***P,0.001. (B–D) Compared with
saline-treated WT mice (n = 8), SKF38393-treated WT mice (n = 9) exhibit
no significant changes of serum levels of triglycerides (TG), cholesterol
(Chol) and blood glucose (Gluc). In SKF38393-treated ros mice, serum
levels of Chol, TG and Gluc were significantly reduced compared to
saline-treated ros l ittermates. SKF38393 vs. saline, Chol:
3.4360.08 mmol/L (n = 9) vs. 3.8660.05 mmol/L (n = 7); TG: 1.29 6
0 .06 mmol/L (n = 8) vs . 1 .6360.01 mmol/L (n = 7) ; Gluc :
11.760.57 mmol/L (n = 9) vs. 14.6760.46 mmol/L (n = 7). **P,0.01. (E)
Total distances traveled during the period of 30 min to 60 min after
SKF38393 treatment were increased in both WT and ros mice. However,
the distance traveled in ros mice was greater than that in WT
(***P,0.001).
doi:10.1371/journal.pgen.1004124.g007
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However, reduced spontaneous locomotor activity was reported in
a line of D1r-KO mutants [38]. Although the number of plasma
membrane D1R in ros mice is about 65% (34%/51.7%) of the WT
mice (Fig. 4C), the ros mutant does not mimic the D1r+/2 mice as
the total number of D1R is unchanged but redistributed mainly
from the plasma membrane to ER. The other significant
difference is that SLC35D3 is selectively expressed in striatal
D1R-expressing neurons which may manifest specific effects
related to D1R reduction. The D1r-KO mice in contrast may
have additional defects given the wider expression of D1R in both
neuronal and non-neuronal tissues. In fact the D1r-KO mice
showed postnatal growth retardation [39]. Thus, complex multiple
interacting effects may preclude the development of obesity in the
D1r+/2 or D1r2/2 mice. In other words, the ros mutant mouse
mimics a D1-neuron specific knockdown of plasma membrane
D1R, rather than mimicking the conventional D1r2/2 or
D1r+/2 mouse.
In contrast to the ob/obmice which develop obesity from the age
of weaning [40], the ros mice exhibited progressive weight gain
starting from 2 months of age. The delayed weight gain in ros mice
with late-onset obesity is still a mystery given that the indicated
protein is present in early stages after birth (Fig. S1). In addition,
the two patients with SLC35D3 mutations were diagnosed with
adult central obesity, which also suggests a late-onset obesity
phenotype in humans.
Our studies have elucidated the underlying genetic entity of a
long-standing unresolved linked locus near the marker D6S1009.
Both mouse and human mutations of the SLC35D3 gene are
associated with MetS, suggesting that SLC35D3 is a novel
candidate gene for MetS. Considering that obesity affects
10,25% of the European population and nearly one third of
the US population [41], a mutational screen of SLC35D3 in the
obese population would be cost-effective as a precursor to potential
D1R agonist treatment.
Obese children receiving D1R agonist treatment reverse weight
gain [42]. Similarly, administration of D1R agonist reversed most
of the phenotype of MetS in ros mice. This effect may be caused by
the stimulation of the residual D1R on the plasma membrane of
ros striatum, or redirection of the ER-retained D1R to plasma
membrane for its signaling. In addition, the reversible phenotypes
upon D1R agonist treatment suggest that the reduced D1R
numbers on the plasma membrane could be the primary cause of
MetS in the ros mutant mice, although we have not excluded the
effects on the substantia nigra and olfactory bulb where SLC35D3
are also expressed (Fig. 3A). SLC35D3 deficiency caused obesity
primarily via effects on physical activity levels, supporting that
genetic factors could be a component of low physical activity [43].
As reduced physical activity is the primary consequence of
impaired D1R signaling, encouraging elevations in physical
activity in these patients might be an alternative way to prevent
or alleviate their symptoms of obesity [44].
Materials and Methods
Mice
The ros mutant (ros2/2) [10] and control C3H/HeSnJ mice
(wild-type, WT) were originally obtained from Dr. Richard T.
Swank’s laboratory and bred in the animal facility of the Institute
of Genetics and Developmental Biology (IGDB), Chinese Acad-
emy of Sciences. To ensure the genotypes of ros2/2 and wild-
type, we developed a PCR method of genotyping based on the
nature of the insertional mutation in the Slc35d3 gene [10]. For the
locomotion tests, only male mice of each genotype at 12 weeks old
were selected to control for potentially confounding hormonal
effects during the estrous cycle in females. Mice were housed in a
room with a 12-hr light/dark cycle (lights on at 7:30 a.m. and off
at 7:30 p.m.) with access to food and water ad libitum. For other
phenotypic analyses, males at 24 weeks of age were used except for
those specified in figure legends or materials and methods.
Study subjects
We recruited 363 unrelated Chinese Han patients with MetS
from The Affiliated Hospital of Qingdao University Medical
College and The Affiliated Children’s Hospital of Nanjing Medical
University, and 217 unaffected individuals from Beijing Tongren
Hospital of Capital Medical University. The patients were
diagnosed as MetS according to the guidelines of Interna-
tional Diabetes Federation (IDF) [15] and central obesity in
China [16]. In brief, MetS is diagnosed as abdominal obesity
(or central obesity) with any two of the following parameters, 1)
TG.1.7 mmol/L, 2) HDL,1.03 mmol/L (male) or,1.29 mmol/L
(female), 3) blood pressure .130/85 mmHg, 4) fasting plasma
glucose .5.6 mmol/L. For the diagnosis of abdominal obesity in
Chinese population, we choose either 1) BMI .28 as general
obesity or 2) BMI between 24 to 28 as overweight, and waist
circumference .90 cm (male) or .85 cm (female). Eight mililiter
peripheral blood samples were collected from all subjects
participating in this study. We designed primers for amplifying
the two exons and about 1 kb upstream of the human SLC35D3
gene. Amplified PCR products were subjected to direct sequenc-
ing by an ABI PRISM 3700 automated sequencer (Applied
Biosystems, Foster City, CA).
Measurements of obesity features and metabolites in
mice
Growth curves for males were obtained by measuring body
weight once a month from 4 to 24 weeks of age. For determination
of body length, mice were anesthetized and fully extended to
measure the naso-anal distance. Epididymal and perirenal fat pads
were harvested from male mice and weighed. Blood was collected
by cardiac puncture after an overnight fast for measuring blood
glucose, serum cholesterol and triglycerides by colorimetric kit
assays (Leadman, Beijing, China) and analyzed using an automatic
biochemical analyzer (Hitachi, Tokyo, Japan). Insulin was
measured by a rat/mouse insulin enzyme-linked immunoassay
(ELISA) Kit on non-fasted mice (Millipore, Bedford, MA, USA).
For the insulin tolerance test (ITT) and glucose tolerance test
(GTT), fasting plasma glucose levels were measured (16 hours fast,
blood taken from the tail vein) using a glucosimeter (Teromo,
Japan). Then insulin (Roche Diagnostics, Switzerland) was injected
intraperitoneally (1 U/kg) and blood glucose was measured again
at 15, 30, 60, 90 and 120 min post injection. Alternatively, D-
glucose (Sigma-Aldrich, St. Louis, Missouri, USA) was injected
intraperitoneally (2 g/kg body weight) and blood glucose was
measured again at 15, 30, 60 and 120 min post injection.
Spontaneous locomotor activity
Mice were pre-exposed to the chamber before testing to allow
environmental habituation, and activity was monitored under
indirect dim light and sound-attenuated conditions. A single
mouse was placed in a chamber (40 cm length640 cm
width645 cm height) for 30 min. Total distance traveled, average
velocity and total movement duration measured spontaneous
activity. All these parameters were measured by JLBehv software
(JLGY, Shanghai, China). Behavioral testing was performed
between 8:00 and 12:00 a.m.
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Food intake
Before measurement of daily food intake, mice fed ad libitum
were individually housed for 3 days to allow environmental
habituation. Food was measured at 3:00 p.m. each day for 7
consecutive days.
VO2 and VCO2 measurements
Mice aged 8 to 12 weeks (prior to development of obesity) were
measured using an indirect calorimetry system (Oxymax, Ohio,
USA). Oxygen consumption, CO2 production and physical activity
(beam breaks) were recorded at 30-min intervals for 5 consecutive
days (48 times a day). Volume of oxygen consumption (VO2) and
carbon dioxide production (VCO2) were measured using electro-
chemical and spectrophotometric sensors respectively. Oxygen
consumption data were converted to energy expenditure (Watts)
using the measured RQ values using procedures outlined in Arch et
al [45]. To report the total energy expenditure we averaged the 48
measurements collected each day across days 2 to 5, allowing the
animals to acclimate during the first 24 h in the chambers [13]. We
recorded simultaneously the physical activity levels of the mice.
Typical temporal patterns of oxygen consumption and physical
activity are shown in Figs. S2A and S2B respectively. To establish
the resting metabolic rate we used two different strategies. First we
summarized all the half hourly oxygen consumption data in a
histogram and then calculated the mean of the lowest 5% of values.
Typical histogram for the data shown in Fig. S2A is shown in Fig.
S2C. A second method was to use the regression approach outlined
by Nonogaki et al [46]. This involved plotting the time matched
data for VO2 and physical activity levels (Fig. S2D) and then
evaluating the resting metabolic rate from the intercept of a fitted
linear regression model. The relationship between total metabolic
rate and body weight for each genotype is shown in Fig. 2E, and that
for the two resting metabolic rate approaches in Figs. 2F and 2G
respectively. Following derivation of the total and resting rates of
metabolism we corrected for the potentially confounding effects of
body weight (Figs. 2E–2G) as recommended in Arch et al [45] and
Tschop et al [13].
Treatment of D1 receptor agonists on mice
Twenty-four to 25-week-old male mice of each genotype
received a daily intraperitoneal injection of dopamine D1 receptor
SKF38393 (20 mg/kg) (Sigma-Aldrich) for a period of 12 days.
Saline-treated mice served as controls. Body weight in all mice was
measured on the fourteenth day. Blood glucose, serum cholesterol
and triglycerides, and locomotor activities were measured as
described above.
cAMP ELISA measurement
The dorsal striatum of mice was dissected as above and
homogenized in Buffer A (10 mM Tris pH 7.4, 1 mM EDTA,
30 mM leupeptin, 1 mM pepstatin A) with 10% sucrose. Mem-
branes were isolated by centrifugation (65 min at 100,000 g) onto
a cushion of Buffer A with 44.5% (w/v) sucrose. The membranes
at the interface were transferred to a new tube and washed twice
with Buffer A and collected by centrifugation (30 min at
100,000 g). Protein concentrations were determined with Protein
Assay (Bio-Rad, Hercules, CA, USA). Adenylyl cyclase activity
was determined by incubating membrane protein (20 mg) at 30uC
for 10 min in 0.1 ml of buffer containing 10 mM imidazole
(pH 7.4), 0.2 mM EGTA, 0.5 mM MgCl2, 0.5 mM DTT,
0.1 mM ATP, 0.5 mM IBMX, and 10 mM D1 receptor agonists
SKF82958 (Sigma-Aldrich). Reactions were terminated by placing
the tubes into boiling water for 2 min. The cAMP concentrations
were measured using the Direct cAMP Enzyme-linked Immuno-
assay Kit (Sigma-Aldrich) following the manufacturer’s instruc-
tions. Optical density was measured at 405 nm by a microplate
reader (Bio-Rad).
Antibodies
The polyclonal rabbit anti-mouse SLC35D3 antiserum (1:1000)
for immunoblotting (WB) was prepared using the purified C-
terminal 322–422aa peptide as an antigen. The monoclonal
mouse anti-GFP (1:1000) and polyclonal rabbit anti-Myc (1:1000)
were obtained from Santa Cruz Biotechnology (Santa Cruz, CA,
USA). Monoclonal mouse anti-Flag antibody (Sigma-Aldrich) was
used for WB (1:7000) and immunocytochemical (ICC) analysis
(1:3000). Mouse monoclonal antibody against calnexin (1:200) for
ICC was purchased from Abcam (Cambridge Science Park,
Cambridge, UK). Mouse monoclonal antibody against D1
receptor (Chemicon, Temecula, CA, USA) was used for WB
(1:600) and ICC (1:300). Polyclonal rabbit anti-D2 receptor
(Millipore) was used for WB (1:2000). Mouse polyclonal antibody
against GM130 for ICC (1:500) was a kind gift from Dr. S. Bao
(IGDB, CAS, China). Polyclonal rabbit anti-LAMP3 (Chemicon)
was used for ICC (1:200). Rabbit polyclonal anti-SEC61B
antibody was purchased from Millipore and used for ICC
(1:600). Mouse monoclonal anti-EEA1 was from BD Biosciences
(Franklin Lakes, NJ, USA) for ICC (1:500). Rabbit polyclonal
anto-GluR1 was from Millipore for WB (1:1000). Goat polyclonal
anti-BIP was from Santa Cruz Biotechnology for WB (1:400).
Mouse monoclonal anti-b-actin (Sigma-Aldrich) was used for WB
(1:10000). Alexa Fluor 594-conjugated donkey anti-mouse and
donkey anti-rabbit IgG (H+L) were purchased from Molecular
Probes (Invitrogen, Carlsbad, CA, USA).
Western blotting
Cell lysates, immunoprecipitates or tissue lysates were combined
with loading buffer and subjected to 8–12% SDS polyacrylamide
gel electrophoresis (SDS-PAGE). Proteins were blotted onto
polyvinylidene difluoride membranes in phosphate buffer with
0.1% Tween-20 (PBST), blocked for 1 h in 5% non-fat dry milk/
PBST and probed for 2 h with primary antibodies at room
temperature. The membranes were rinsed three times (10 min
each) with PBST prior to incubation with appropriate peroxidase-
conjugated secondary antibodies (Santa Cruz Biotechnology) and
developed with enhanced chemiluminescence (Amersham Biosci-
ences, Piscataway, NJ, USA).
Constructs and co-immunoprecipitation
We prepared constructs for co-immunoprecipitation and
immunofluorescence experiments. Mouse entire coding regions
of wild-type Slc35d3 (RefSeq, NM_029529, http://www.ncbi.nlm.
nih.gov/refseq/), D1r (RefSeq, NM_010076), D2r (RefSeq,
NM_010077), and human SLC35D3 (RefSeq, NM_001008783)
were subcloned into the pEGFP-C2 or -N2 vector (with GFP-tag),
pCMV-tag2B vector (with Flag-tag) and pCMV-tag3B vector
(with Myc-tag) as specified in the figures. The fragments of mouse
SLC35D3 and mouse D1R specified in figure legends were
generated by subcloning. The mutant human SLC35D3 constructs
(DK404 and insL201) were generated by site-directed mutagenesis
(Takara, Japan) using human wild-type SLC35D3 construct.
Transfected HEK-293T cells grew to confluency on 6-well
plates. Cells were harvested and lysed in 50 mM Tris-HCl
(pH 7.4), 150 mM NaCl, 1 mM EDTA, 1% Triton X-100 and
protease inhibitors. Cell lysates were centrifuged at 18,000 g for
10 min, and the supernatant was collected and recentrifuged. The
supernatant was incubated overnight with 3 mg mouse monoclonal
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anti-FLAG M2 antibody (Sigma-Aldrich) and washed 6 times with
ice-cold wash buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl).
The samples were eluted with elution buffer (5 mg/ml 36 FLAG
peptide) and subjected to SDS-PAGE and Western blotting with
anti-Myc or anti-Flag antibody as described above.
Histological and immunohistochemical staining
Mice were perfused through the heart with 4% paraformalde-
hyde in 0.1 M phosphate buffer (pH 7.4) under deep pentobar-
bital anesthesia. The brains were removed, and 20 mm frozen
sections in the coronal plane were prepared for hematoxylin and
eosin (H–E) or immunohistochemical staining (IHC). The H–E
staining followed routine procedures. A standard H–E staining
protocol was applied to sections of adipose tissue, liver, pancreas
and skeletal muscle. For IHC, the endogenous peroxidase activity
was blocked by treatment with 0.3% hydrogen peroxide in
methanol, sections were blocked with 0.01 M PBS containing 10%
goat serum and were then incubated overnight at 4uC with the
mouse monoclonal antibody against D1R (1:400). Following
0.01 M PBS rinses, sections were incubated in a biotinylated
secondary antibody (Zhongshan Goldenbridge, Beijing, China) for
an hour at room temperature, treated for another hour at room
temperature with peroxidase-ligated streptavidin. The results were
captured by a TS100 microscope (Nikon, Tokyo, Japan).
Immunofluorescence confocal imaging
HEK293T cells transfected with EGFP-SLC35D3 (wild-type or
mutant or other constructs as specified in the results or figure
legends) were grown on glass cover slips in 24-well plates until 30–
50% confluence. 18–20 hrs after transfection, they were fixed with
freshly prepared 4% paraformaldehyde for 10 min. Cells were
washed 3 times with 0.01 M phosphate buffer (pH 7.4). The
permeabilization of cells was carried out in the presence of 0.3%
Triton X-100 in PBS for 10 min. After blocking in 0.01 M PBS
containing 1% BSA for 1 hr at 37uC, fixed cells were incubated
with various antibodies as indicated in the results overnight at 4uC.
Cells were then washed 3 times in 0.01 M PBS containing 0.1%
Triton X-100 before incubating with Alexa Fluor 594-conjugated
secondary antibody at 1:2000 dilution for 1 h at 37uC. Cells were
then washed 3 times before glass cover slips were mounted. Images
were acquired with an 6100 lens on a D-ECLIPSE-si confocal
microscope (Nikon).
Immuno-electronic microscopy examination
Mice were anesthetized with pentobarbital (0.1 g/kg, Sigma-
Aldrich). Brains were separated and cut by a vibratome (DSK,
model DTK-1000, Japan). The striatum was fixed with 2%
paraformaldehyde, 2.5% glutaraldehyde and 0.1% tannic acid in
0.1 M natrium cacodylicum. Then sections were rinsed and
postfixed with 1% osmium tetroxide for 30 min. After washing,
the sections were dehydrated in an ascending series of dilution of
acetone and impregnated in Epon 60uC, 24 hours. Ultrathin
(70 nm) sections were collected on nickel grids, rinsed and
incubated with mouse anti-D1R (1:10) or rabbit anti-SEC61B
(1:50) in 1% BSA buffer overnight at 4uC, washed and incubated
with 10 nm gold-anti-mouse IgG or 15 nm anti-rabbit IgG (1:50).
Sections were observed in JEM 2000 electron microscope (Japan).
All the reagents were purchased from Electronic Microscope
Science (EMS, Hatfield, PA, USA).
OptiPrep gradient assay
The dissected striatum was immediately homogenized with 1 ml
HB lysis buffer (250 mM sucrose, 20 mM Tris-HCl, pH 7.4,
1 mM EDTA). The sample was placed onto the top of an 11 ml
continuous 5%–20% Optiprep (Axis-Shield, Norway) gradient in
HB buffer. The gradient was centrifuged at 200,000 g
(34100 rpm) for 14 hours in a Beckman SW41 rotor. Twenty-six
fractions (400 ml each) were collected from the top using auto-
collector (BioComp, USA). Equal aliquots from each fraction were
analyzed for immunoblotting.
For the fractionation assay, the dissected striatum was
immediately homogenized with 200 ml HB lysis buffer. 800 ml
20% Optiprep and 800 ml 5% Optiprep in HB buffer were placed
into the tube constitutively. The tissue lysate was placed onto the
top of the gradient. The sample was centrifuged at 28,000 rpm
(TLS-55, Beckman, USA) for 14 hours. Eighteen fractions (100 ml
each) were collected from the top. Based on the pilot Western
assay, the fractions were combined as the 1–10th tube (mostly
cytoplasm fraction) and the 11–18th tube (mostly plasma
membrane fraction) respectively. Equal aliquots from each fraction
were analyzed for immunoblotting.
Data collection and analyses
cAMP ELISA was performed in duplicate and was repeated
three or four times. The standard curves were generated using
non-linear regression curve fitting. The specific protein bands on
Western blots were scanned and analyzed using the software
program NIH Image J. All data were obtained from at least three
independent experiments. Data were expressed as mean 6 SEM
and statistical significance was tested by Student’s t-test. Data from
the calorimetry system was tested by ANCOVA. Distribution of
gold-labeled particles in immuno-EM pictures were counted and
statistical significance was tested by Chi-square test. Intensities of
immunofluorescence in cultured cells were analyzed using NIH
Image J.
Ethics statements
All mouse procedures were approved by the Institutional
Animal Care and Use Committee of IGDB (mouse protocol
KYD2006-002). The study of human subjects was approved by the
Bioethic Committee of IGDB, Chinese Academy of Sciences (IRB
approval number, IGDB-2011-IRB-002). The study was conduct-
ed according to the Declaration of Helsinki Principles. Written
informed consents were obtained from all subjects.
Supporting Information
Figure S1 Expression of SLC35D3 in postnatal mouse striatum.
Wild-type (WT) mouse striatum were dissected from mice at
different postnatal ages (0.5, 1, 2, 3, 5, 6 months) and the lysates
were applied to Western blotting analyses. The striatum from
6-month-old ros mice were used as a control. b-actin was a loading
control. No apparent expression level changes were noted in the
blots. Two independent studies were performed.
(TIF)
Figure S2 Analysis strategy for oxygen consumption and energy
expenditure measurements. (A) Typical pattern of oxygen
consumption measured at 30 min intervals over a 5 day test
period. (B) Simultaneous measurements of physical activity to the
measurements of oxygen consumption shown in (A). (C)
Histogram of the half hourly measurements in (A) and the cut-
off used to determine the minimal (or resting) metabolic rate. (D)
Plot of oxygen consumption against physical activity levels for the
data in (A) and (B), showing the fitted regression and the estimated
resting metabolism.
(TIF)
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Figure S3 D2R expression and distribution in striatum. (A) No
significant change of total level of D2R in striatum was observed
between wild-type (WT) and ros mutant (P.0.05). Quantification
of the intensities was calculated from three independent experi-
ments. (B) Striatum lysates were fractionated into plasma
membrane (PM) and cytoplasm (cyto) containing intracellular
organelles. Distribution of D2R on the plasma membrane was
normal in the ros mice compared to the wild-type (WT).
(TIF)
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